GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 9 Meters Biopharma Inc (OTCPK:NMTRQ) » Definitions » Enterprise Value

9 Meters Biopharma (9 Meters Biopharma) Enterprise Value : $0.00 Mil (As of Jun. 09, 2024)


View and export this data going back to 2016. Start your Free Trial

What is 9 Meters Biopharma Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-42.86 Mil. Therefore, 9 Meters Biopharma's EV-to-EBIT ratio for today is 0.00.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 was $-42.86 Mil. Therefore, 9 Meters Biopharma's EV-to-EBITDA ratio for today is 0.00.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, 9 Meters Biopharma's Enterprise Value is $0.00 Mil. 9 Meters Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $0.00 Mil. Therefore, 9 Meters Biopharma's EV-to-Revenue ratio for today is .


9 Meters Biopharma Enterprise Value Historical Data

The historical data trend for 9 Meters Biopharma's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

9 Meters Biopharma Enterprise Value Chart

9 Meters Biopharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.73 20.63 138.16 205.91 23.51

9 Meters Biopharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 117.67 38.26 58.37 23.51 18.16

Competitive Comparison of 9 Meters Biopharma's Enterprise Value

For the Biotechnology subindustry, 9 Meters Biopharma's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


9 Meters Biopharma's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Enterprise Value distribution charts can be found below:

* The bar in red indicates where 9 Meters Biopharma's Enterprise Value falls into.



9 Meters Biopharma Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

9 Meters Biopharma's Enterprise Value for the fiscal year that ended in Dec. 2022 is calculated as

9 Meters Biopharma's Enterprise Value for the quarter that ended in Mar. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


9 Meters Biopharma  (OTCPK:NMTRQ) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

9 Meters Biopharma's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-42.863
=0.00

9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.86 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

9 Meters Biopharma's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=0.000/-42.855
=0.00

9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-42.86 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

9 Meters Biopharma's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=0.000/0
=

9 Meters Biopharma's current Enterprise Value is $0.00 Mil.
9 Meters Biopharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


9 Meters Biopharma Enterprise Value Related Terms

Thank you for viewing the detailed overview of 9 Meters Biopharma's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


9 Meters Biopharma (9 Meters Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.
Executives
Bethany Sensenig officer: Chief Financial Officer C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
John Temperato director, officer: Chief Executive Officer C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Samantha Ventimiglia director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Edward J Sitar officer: Chief Financial Officer 39 FLAMING ARROW ROAD, MAHWAH NJ 07430
Orbimed Israel Biofund Gp Limited Partnership 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629
Yehuda Michael Rice director 155 WALNUT STREET, ENGLEWOOD NJ 07631
Nissim Darvish director, 10 percent owner C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Orbimed Israel Gp Ltd. 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629
Sandeep Laumas director, officer: Executive Chairman 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Jay P. Madan director, officer: President 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Roy Proujansky director 144 PAU NEL DRIVE, LANDENBERG PA 19350
Christopher P. Prior director, officer: Chief Executive Officer 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
June Sherie Almenoff officer: COO and Chief Medical Officer C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019

9 Meters Biopharma (9 Meters Biopharma) Headlines